Agilent Technologies
A
$135.05
-0.68%
Agilent Technologies Inc. is a leading life science and diagnostic firm that provides measurement technologies and solutions across three operating segments: life science and diagnostics, cross lab operations (consumables and services), and applied end markets. The company is a market leader with a distinct competitive identity built on its heritage from Hewlett-Packard and its focus on serving 'sticky' end markets like biopharmaceuticals, chemicals, and advanced materials, which account for over half its sales. The current investor narrative is driven by robust operational momentum, highlighted by a recent strong quarterly earnings beat and a raised full-year profit forecast, alongside strategic moves such as the acquisition of Biocare Medical to accelerate growth in the high-margin pathology market.…
A
Agilent Technologies
$135.05
Related headlines
Investment Opinion: Should I buy A Today?
Rating & Thesis: Hold. Agilent presents a mixed picture of strong fundamentals and operational execution offset by a premium valuation and recent technical weakness, making it a Hold for existing investors but not a compelling new Buy at current levels. The absence of a clear analyst consensus target complicates the upside assessment, but the recent bullish analyst reiterations (Overweight/Buy) around the earnings beat provide a positive sentiment backdrop.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The stock trades at a premium trailing P/E of 31.79x, which is high historically, though the forward P/E of 20.54x is more reasonable if growth materializes. 2) Revenue growth remains positive at 6.96% YoY, but the sequential decline is a concern. 3) Profitability metrics are robust (ROE 19.33%, Net Margin 18.75%), and free cash flow generation is strong at $993M TTM. 4) The stock has already rallied 21.77% in one month on the earnings news, potentially pricing in near-term optimism and limiting immediate upside.
Risks & Conditions: The two biggest risks are valuation compression if growth decelerates and a resumption of the prior downtrend if the recent rally fails. This Hold would upgrade to a Buy if the stock consolidates and the forward P/E of 20.54x proves justified by sustained double-digit earnings growth, or if it pulls back towards the $120-$125 support zone offering a better risk/reward. It would downgrade to a Sell if Q2 2026 results show a continuation of the sequential revenue decline and further margin pressure, confirming the bear case. The stock is currently fairly valued to slightly overvalued relative to its own history, demanding flawless execution to support its price.
Sign up to view all
A 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. Agilent is a high-quality company caught between strong fundamentals and a full valuation. The recent earnings-driven surge has improved the technical picture, but the stock remains in a longer-term downtrend and trades at a premium. The forward P/E of 20.54x is the key metric to watch; if the company can deliver earnings growth to justify it, the stock can grind higher. The stance would upgrade to Bullish on a confirmed breakout above $150 with sustained volume, or downgrade to Bearish if the stock fails to hold above $130 and the sequential revenue weakness persists into the next quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $175.57 and implied upside of +30.0% versus the current price.
Average Target
$175.57
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$108 - $176
Analyst target range
Analyst coverage for Agilent appears limited in the provided dataset, with only 7 analysts providing estimates for revenue and EPS, and no explicit consensus price target, recommendation distribution, or target range data is available. Therefore, there is insufficient analyst coverage data available to determine a consensus price target, implied upside/downside, or a clear Buy/Hold/Sell sentiment. The implication of limited explicit coverage is that while the company is a sizable $41.4 billion market cap firm, the absence of a broad, published target range may contribute to higher volatility and less efficient price discovery, placing greater emphasis on company-specific fundamentals and quarterly execution. The available institutional ratings show a pattern of reiterated bullish stances (e.g., Morgan Stanley, Barclays, UBS maintaining Overweight/Buy) around the late February 2026 earnings period, with one upgrade from Evercore ISI Group to Outperform in January, indicating generally positive analyst sentiment supportive of the recent stock price recovery.
Bulls vs Bears: A Investment Factors
The bull case, currently strengthened by a powerful post-earnings rally, rests on strong fundamentals, raised guidance, and a healthy balance sheet. The bear case centers on a premium valuation, recent revenue/margin softness, and a still-intact longer-term downtrend. The most critical tension in the investment debate is whether the company's recent Q1 earnings beat and guidance raise mark a sustainable inflection point that justifies its elevated trailing P/E of 31.79x, or if the sequential revenue decline and margin compression signal a more challenging growth environment that will lead to valuation compression. The resolution of this tension will determine if the stock's 21.77% one-month surge is the start of a new uptrend or a bear market rally.
Bullish
- Strong Q1 Beat & Raised Guidance: Recent Q1 2026 earnings beat and raised full-year profit forecast have driven a 21.77% one-month stock surge, signaling robust operational momentum. This positive news catalyzed a sharp reversal from a 6-month downtrend of -11.71%.
- Healthy Profitability & Cash Flow: The company maintains strong profitability with a Q1 net margin of 16.96% and an operating margin of 19.63%, supported by a 52.61% gross margin. Strong free cash flow generation of $993M TTM funds dividends (21.64% payout ratio) and share buybacks ($152M in Q1).
- Solid Balance Sheet & Low Leverage: A robust balance sheet features a current ratio of 1.96 and a manageable debt-to-equity ratio of 0.50. This provides financial flexibility for strategic acquisitions, like Biocare Medical, and to weather economic downturns.
- Resilient & Diversified End Markets: Over half of sales come from 'sticky' end markets like biopharmaceuticals and chemicals, providing revenue stability. Segment diversification is evident with CrossLab ($758M), Life Sciences ($679M), and Applied Markets ($361M) contributing in Q1.
Bearish
- Elevated Trailing Valuation: The trailing P/E of 31.79x is at the higher end of the stock's historical range (approx. 24x-37x), suggesting limited margin for error. The PS ratio of 5.96x and PEG ratio of 9.41 also indicate a premium valuation that requires sustained high growth.
- Recent Revenue & Margin Pressure: Q1 2026 revenue of $1.798B declined sequentially from $1.861B in Q4 2025, indicating near-term softness. Gross margin compressed to 52.61% from 53.48% YoY, suggesting potential cost pressures or unfavorable product mix.
- Pronounced Downtrend & High Volatility: The stock remains down -11.71% over the past six months and has underperformed the SPY by -22.41% over that period, indicating a weak longer-term trend. A beta of 1.22 and a 29.87% max drawdown highlight above-market volatility and downside risk.
- Limited Analyst Coverage & Targets: Only 7 analysts provide estimates, with no clear consensus price target available. This limited coverage can lead to less efficient price discovery and higher volatility, as seen in the recent sharp swings.
A Technical Analysis
The stock is in a pronounced downtrend over the past six months, evidenced by a -11.71% change over that period, but has recently shown a sharp recovery attempt. As of the latest close at $135.53, the price is trading at approximately 52% of its 52-week range ($108.35 to $160.27), indicating it is positioned near the midpoint after a significant decline, which may suggest a potential value zone but also reflects substantial prior weakness. Recent momentum has been exceptionally strong, with the stock surging 21.77% over the past month, dramatically outperforming the SPY's 6.31% gain, as indicated by a relative strength of +15.46; this powerful short-term rally contrasts sharply with the negative 1-year relative strength of -8.57, signaling a potential trend reversal or a significant mean reversion bounce from deeply oversold levels. Key technical levels are the 52-week low of $108.35, which now serves as critical support, and the 52-week high of $160.27, which represents formidable resistance; a sustained breakout above the recent recovery highs could signal a more durable recovery, while a failure and breakdown below support would reaffirm the prior downtrend. The stock's beta of 1.22 indicates it is 22% more volatile than the broader market, which is important for risk management, especially given the stock's recent 29.87% maximum drawdown and elevated volatility during its recovery phase.
Beta
1.22
1.22x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$160
Price range past year
Annual Return
+21.6%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +17.9% | +5.4% |
| 3m | +12.0% | +10.9% |
| 6m | -8.9% | +11.0% |
| 1y | +21.6% | +28.1% |
| ytd | -2.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Revenue growth has been modest but positive, with the most recent quarterly revenue of $1.798 billion representing a 6.96% year-over-year increase; however, examining the sequential trend, revenue declined from $1.861 billion in the prior quarter (Q4 2025), indicating some near-term pressure or seasonality. Segment data from the latest quarter shows Agilent CrossLab as the largest contributor at $758 million, followed by Life Sciences and Applied Markets at $679 million and Applied Markets at $361 million, providing a diversified revenue base. The company remains solidly profitable, reporting net income of $305 million for Q1 2026 and a net margin of 16.96%; gross margin was healthy at 52.61%, though it has compressed slightly from 53.48% in the year-ago Q1, indicating some pressure on input costs or product mix. Profitability metrics are robust, with a return on equity (ROE) of 19.33% and a return on assets (ROA) of 8.64%, reflecting efficient use of capital, while the operating margin for the quarter was 19.63%, demonstrating strong operational control. The balance sheet is healthy with a current ratio of 1.96 and a debt-to-equity ratio of 0.50, indicating manageable leverage and good liquidity. Cash flow generation is strong, with trailing twelve-month free cash flow of $993 million and operating cash flow of $268 million in the latest quarter, providing ample internal funding for growth initiatives, dividends (payout ratio 21.64%), and share repurchases, as evidenced by $152 million in buybacks during Q1.
Quarterly Revenue
$1.8B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$993000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Given the company's consistent profitability with net income of $305 million, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 31.79x, while the forward PE is significantly lower at 20.54x; this substantial gap implies the market is pricing in expectations for meaningful earnings growth and a recovery in profitability over the next year. Compared to sector averages, Agilent's trailing PE of 31.79x and Price-to-Sales (PS) ratio of 5.96x are not directly comparable without provided industry benchmarks, but the company's premium valuation is typically justified by its market leadership, high margins (gross margin 52.43%, operating margin 21.29%), and exposure to resilient end markets. Historically, the stock's current trailing PE of 31.79x is above its recent quarterly historical range, which has fluctuated between approximately 24x and 37x over the past two years, suggesting the market is currently pricing the stock at a relatively elevated level within its own history, likely reflecting optimism around the recent earnings beat and raised guidance.
PE
31.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Agilent's primary financial risk is its premium valuation, with a trailing P/E of 31.79x and a PEG ratio of 9.41, which leaves the stock vulnerable to significant multiple compression if growth disappoints. While the balance sheet is strong (D/E 0.50), the company faces margin pressure, with Q1 gross margin compressing 87 bps YoY to 52.61%, and a sequential revenue decline from $1.861B to $1.798B, raising questions about near-term demand. Dependence on continued high growth to justify its valuation is a key risk, as a slowdown could trigger a re-rating lower.
Market & Competitive Risks: The stock's market risk is elevated, with a beta of 1.22 indicating 22% higher volatility than the broader market, which was evident during its 29.87% maximum drawdown. Trading at a trailing P/E near the top of its historical range, the stock is exposed to valuation compression risk, especially in a rising rate environment that pressures growth stock multiples. Competitive and regulatory risks in its core life sciences and diagnostics markets could pressure pricing and market share, though its diversified segment revenue provides some buffer.
Worst-Case Scenario: The worst-case scenario involves a failure to sustain the post-earnings momentum, with a subsequent earnings miss leading to a rapid de-rating. This could be triggered by a deeper-than-expected slowdown in biopharma capital spending, integration issues with the Biocare acquisition, or further gross margin erosion. In this adverse scenario, the stock could realistically revisit its recent 52-week low of $108.35, representing a downside of approximately -20% from the current price of $135.53, potentially exacerbated by its high beta and the lack of a broad analyst target floor for support.
FAQ
The key risks are: 1) Valuation Risk: The high trailing P/E (31.79x) and PEG ratio (9.41) make the stock vulnerable to multiple compression if growth slows. 2) Operational Risk: Recent sequential revenue decline and gross margin compression (52.61% in Q1 vs. 53.48% YoY) could signal underlying demand or cost pressures. 3) Market Risk: A beta of 1.22 means the stock is 22% more volatile than the market, as evidenced by its 29.87% max drawdown. 4) Execution Risk: Successful integration of the Biocare Medical acquisition is critical for achieving strategic growth goals in pathology.
The 12-month outlook presents three scenarios with associated probabilities. The Base Case (55% probability) sees the stock trading between $135 and $150 as it consolidates recent gains and grows into its forward P/E. The Bull Case (30% probability) targets $155-$165 on sustained execution and multiple expansion. The Bear Case (15% probability) could see a retest of the $108-$125 range if growth disappoints and the valuation compresses. The most likely scenario is the Base Case, which assumes the company meets its raised guidance but struggles to command a higher valuation multiple in the near term.
A appears fairly valued to slightly overvalued based on current metrics. The trailing P/E of 31.79x is at the higher end of its historical range and reflects a premium for its quality and defensive growth. The more relevant forward P/E of 20.54x is more reasonable and implies the market expects solid earnings growth. Compared to sector averages (data not provided), its Price-to-Sales of 5.96x is likely at a premium. The valuation is not cheap, but it is justified if the company meets its raised guidance; it is overvalued if growth disappoints.
A is a Hold, not a clear-cut Buy at the current price of $135.53. For investors seeking a high-quality, defensive growth name, it offers strong fundamentals including a 19.33% ROE and robust free cash flow. However, the recent 21.77% rally may have captured near-term upside, and the trailing P/E of 31.79x is elevated, demanding flawless execution. It could be a good buy on a pullback towards $125 for long-term holders, but the risk/reward is balanced at these levels given the stock's high beta of 1.22 and recent volatility.
A is best suited for a long-term investment horizon of 3-5 years. Its business model, serving sticky end-markets like biopharma, rewards patient investors through economic cycles. The stock's high beta (1.22) and recent 29.87% drawdown make it less ideal for short-term trading, as volatility can be punishing. For long-term holders, the company's strong cash flow generation (FCF $993M TTM), dividend (0.68% yield), and share buyback program provide tangible returns. A minimum holding period of 12-18 months is suggested to allow the company's strategic initiatives and the Biocare integration to play out.
